The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.
 
John Mascarenhas
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; CTI BioPharma Corp; Galecto; Geron; GlaxoSmithKline; Incyte; Kartos Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Merck; Novartis; Pharmaessentia; Roche/Genentech; Sierra Oncology; Sumitomo Pharma Oncology
Research Funding - Abbvie (Inst); Celgene/Bristol-Myers Squibb (Inst); CTI BioPharma Corp (Inst); Geron (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pharmaessentia (Inst); Roche/Genentech (Inst)
 
Keri Renee Maher
No Relationships to Disclose
 
Raajit Rampal
Honoraria - Protagonist Therapeutics
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; CTI BioPharma Corp; Disc Medicine; Galecto; Incyte; Karyopharm Therapeutics; Novartis; Pharmaessentia; Promedior; SERVIER; Sierra Oncology; Stemline Therapeutics; Sunimoto Dainippon; Zentalis
Research Funding - Constellation Pharmaceuticals; Ryvu Therapeutics; Stemline Therapeutics; Zentalis
Travel, Accommodations, Expenses - Incyte; Sierra Oncology
 
Prithviraj Bose
Honoraria - Abbvie; Blueprint Medicines; BMS; Cogent Biosciences; CTI BioPharma Corp; GlaxoSmithKline; Incyte; Ionis Pharmaceuticals; Jubilant Therapeutics; Karyopharm Therapeutics; Morphic Therapeutic; MorphoSys; Novartis; Pharmaessentia
Consulting or Advisory Role - Ono Pharmaceutical; Sierra Oncology
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Geron (Inst); Incyte (Inst); Ionis Pharmaceuticals (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Karyopharm Therapeutics (Inst); MorphoSys (Inst); Telios (Inst)
 
Nikolai Alexandrovich Podoltsev
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Constellation Pharmaceuticals; CTI BioPharma Corp; Incyte; Novartis
Research Funding - AI Therapeutics (Inst); Aptos Biosciences (Inst); Arog (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Jazz Pharmaceuticals (Inst); Kartos Therapeutics (Inst); Pfizer (Inst); Samus Therapeutics (Inst); Sunesis Pharmaceuticals (Inst)
Other Relationship - Cogent Biosciences
 
Junshik Hong
Honoraria - BMS Korea; Novartis; PharmaEssentia Korea
Consulting or Advisory Role - Bridgebio
Research Funding - Enzynomics
 
Xulong Wang
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Steve Kye
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Abbvie; Karyopharm Therapeutics; Pfizer; Xencor
Patents, Royalties, Other Intellectual Property - Abbvie
 
Claire Harrison
Honoraria - Abbvie; CTI BioPharma Corp; Geron; GlaxoSmithKline (Inst); Janssen; Novartis
Consulting or Advisory Role - AOP Orphan Pharmaceuticals; BMS; Constellation Pharmaceuticals; CTI; Galecto; Geron; Incyte; Janssen; Keros Therapeutics; MorphoSys; Novartis; Roche
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; CTI BioPharma Corp; Geron; GlaxoSmithKline; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis